BK Virus in Kidney Transplant Recipients: The Influence of Immunosuppression by Barraclough, Katherine A. et al.
Hindawi Publishing Corporation
Journal of Transplantation
Volume 2011, Article ID 750836, 9 pages
doi:10.1155/2011/750836
Clinical Study
BKVirusin KidneyTransplant Recipients:
TheInﬂuenceofImmunosuppression
Katherine A. Barraclough,1 NicoleM.Isbel,1 ChristineE.Staatz,2 and David W.Johnson1
1Department of Nephrology, University of Queensland at the Princess Alexandra Hospital, Brisbane, QLD 4102, Australia
2School of Pharmacy, University of Queensland, St Lucia, Brisbane, QLD 4072, Australia
Correspondence should be addressed to Katherine A. Barraclough, katherine barraclough@health.qld.gov.au
Received 14 January 2011; Revised 5 March 2011; Accepted 27 March 2011
Academic Editor: Bernhard K. Kr¨ amer
Copyright © 2011 Katherine A. Barraclough et al. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
The incidence of BK virus infection in kidney transplant recipients has increased over recent decades, coincident with the use of
more potent immunosuppression. More importantly, posttransplant BK virus replication has emerged as an important cause of
graft damage and subsequent graft loss. Immunosuppressionhas been accepted as a major risk for BK virus replication. However,
the speciﬁc contribution of individual immunosuppressive medications to this risk has not been well established. The purpose of
this paper is to provide an overview of the recent literature on the inﬂuence of the various immunosuppressant drugs and drug
combinations on posttransplant BK virus replication. Evidence supporting the various immunosuppression reduction strategies
utilised in the managementof BK virus will also be brieﬂy discussed.
1.Introduction
Advances in immunosuppressive therapies have markedly
improved short-term kidney transplant outcomes. There has
been a substantial decrease in acute rejection rates, and in
mostcentres,1-yeargraftsurvivalnowexceeds95%[1–3].In
contrast, recent years have seen only minimal gains in long-
term transplant outcomes [4]. Death-censored graft survival
has only marginally increased [1–3], and life expectancy
of kidney transplant recipients (KTxRs) remains markedly
lower than that of the general population [5]. In large
part, this is due to complications associated with life-long
immunosuppression.
Disease associated withBKvirus (BKV)isone suchcom-
plication. BKV is a small, ubiquitous, nonenveloped double-
stranded DNA virus of the polyomavirus family. Its genome
comprises early genes that code for the regulatory small
and large T (LT) proteins and late genes that code for the
viral capsid proteins (VP1, VP2, and VP3) and agnoprotein
[6]. The genome also includes a noncoding control region
(NCCR) that contains the origin of viral replication and the
transcription and promotersequencesthat controlviral gene
expression.
Serological studies indicate that BKV infection has a
worldwide adult seroprevalence rate of around 75% (range
of 46–94% depending on the region studied) [6, 7]. Primary
infection is usually asymptomatic, but BKV establishes
latency in urinary epithelium [6–8]. While reactivation and
urinary shedding occurs in 10% to 60% of immunocom-
petent individuals [7, 9, 10], markedly higher rates have
been reported in immunocompromised individuals [11].
BKV appears to cause clinical disease only in individuals
with changed or altered immune responses. This has been
documented in pregnant individuals, those with human
immunodeﬁciency virus-1 (HIV-1) infection or receiving
chemotherapy, and in bone marrow and solid organ trans-
plant recipients [12].
BKV infection in KTxRs has been described as caus-
ing several diﬀerent manifestations. These include ureteric
stenosis, haemorrhagic cystitis, transient renal dysfunction,
and progressive renal impairment due to BKV-associated
nephropathy (BKVAN) [6]. Of these, BKVAN is the most
common and the most clinically signiﬁcant because of its
association with graft loss [13]. BKVAN was essentially a
nonexistent entity in the 1980s and early 1990s, conﬁrmed
by a study that retrospectively reviewed biopsy slides of2 Journal of Transplantation
kidney transplant patients shedding decoy cells (cells in
the urine that contain viral inclusions) between 1985 and
1996 [14]. However, its incidence has steadily increased
in the subsequent years, with reports from recent decades
describing incidence rates as high as 10% [15]. More
importantly, BKVAN has emerged as an important cause
of graft loss, reported in 0% to 80% of cases depending
on immunosuppressive regimen employed, cohort size,
timing of detection, and management strategy instituted
[6, 13, 16].
Current knowledge regarding risk factors for BKVAN in
the posttransplant period is extremely limited and incon-
sistent. A number of clinical and demographic factors have
been associated with increased risk (Table 1)[ 17–35], but
most have been only variably implicated and have limited
predictive value [36]. More plausible is the notion that risk
of BKVAN is dependent on the interaction of multiple risk
factors [6], with a primary contribution from immuno-
suppression, and additional contributions from such donor,
recipient, and viral factors as those tabulated.
2.Immunosuppressionand BKV
Immunosuppression is the most signiﬁcant and the only
widely accepted risk factor for posttransplant BKV repli-
cation. This is largely because BKV associated disease is
seen only in immunosuppressed populations, and because
multiple studies have shown reductions in BKV replication
following immunosuppression minimisation [6]. However,
the relationship between BKVAN and immunosuppression
remains poorly deﬁned. Particularly, it remains unclear
whether any particular agent can be speciﬁcally implicated,
orwhetheroverallpotencyofimmunosuppressionisrespon-
sible.
2.1.InVitroStudies. Surprisingly,inadditiontoitsimmuno-
suppressive properties, cyclosporine has been shown to
possess antiviral activity in vitro against herpes simplex
virus [38], vaccinia virus [39], HIV-1 [40, 41], and hepatitis
Cv i r u s[ 42–45]. Similarly, some studies have shown a
suppressive eﬀect of mycophenolic acid (MPA; the active
drug moiety of mycophenolate mofetil (MMF) and enteric-
coated mycophenolate sodium (EC-MPS)) on the in vitro
replication of various herpes viruses [46], HIV-1 [47–49],
andhepatitisBvirus[50–52].Basedonthesedata,Acottetal.
[53, 54] investigated the impact of cyclosporine and MPA on
BKV replication using Vero E6 cells of green monkey origin
infected with BKV (VJ isolate) when 70–90% conﬂuence
had been reached. Clinically utilised concentrations of
cyclosporine were shown to not only inhibit the primary
BKVinfection peak, butalso to inhibit BKVreactivation and
NCCR gene rearrangements in a dose-independent manner
[53].Themagnitudesoftheseobservedeﬀectsweresimilarat
all cyclosporine doses tested (200–12800μg/L). No antiviral
eﬀect of cyclosporine was seen on transformed virus or
in cells with high-level infection (>109 copies/mL). In a
separate study, the same group showed a dose-dependent
suppressive eﬀect of clinically relevant concentrations of
Table 1: Factors other than immunosuppression associated with
increased risk of posttransplant BKV replication.
Risk factors Reference
Older age [20, 35]
Male gender [20, 35]
Caucasianrace [18, 35]
Diabetes mellitus [18]
Deceased donor [19]
Greater HLA mismatches [20–22, 35]
Absence of HLA-C7 in donor and recipient [23]
Acute rejection [18, 21, 35]
Recipient seronegativity [25, 33]
Recipient seropositivity [26]
Donor seropositivity [23, 27, 28]
High donor antibody titre [23]
Poor cellular immune response [30–34, 37]
Longer cold ischemic time [35]
Use of ureteral stent [35]
Delayed graft function [35]
More recent transplant year [35]
Lower centre transplant volume [35]
BKV: BK virus; HLA: human leukocyte antigen.
MPA (1–16μg/mL) on early and persistent BKV infection
[54]. In contrast to cyclosporine, when added to culture at
high doses (>8μg/mL), MPA was also able to inhibit high-
level infection, and infection with NCCR rearranged virus.
A concern with both of the above-mentioned studies is
that all results were obtained from a Vero E6 monkey cell
line. This raises the possibility of a cell-speciﬁc eﬀect. To
prove relevance of these ﬁndings to humans, a recent study
investigated the eﬀect of cyclosporine on BKV-(archetype
strain-) infected human proximal renal tubular (HK-2) cells
[55].Cyclosporine(concentrationrangeof0.5–4μg/mL)was
shown to dose-dependently reduce the expression of BKV
LT and VP1 gene transcripts and BKV LT protein and to
prevent the LT protein-regulated increase in early promoter
activity. Interestingly, while actual data was not presented,
this paper also reported that addition of tacrolimus (0.5–
10ng/mL) to culture media had no impact on LT antigen
expression, suggesting against a calcineurin inhibitor class
eﬀect.
Sirolimus has been shown to inhibit the expression of
BKV LT antigen in both immortalized human renal cells and
primary human renal tubular cells [56]. The eﬀect was dose-
dependent, observed across the range of 30 to 150ng/mL.
As stated by the study’s authors’, 30ng/mL represents peak
serum levels of sirolimus in transplant patients, while the
higher concentrations may reﬂect tissue levels. In this study,
use of sirolimus alone had no eﬀect on BKV replication.
However, its use in combination with leﬂunomide led to
signiﬁcant reductions in BKV DNA.
In vitro steroid treatment has been shown to confer
enhanced host cell permissivity for BKV infection. Moens et
al. [57] found that treatment of BKV-infected Vero cells withJournal of Transplantation 3
dexamethasone increased the expression of viral transcripts
(particularlythecapsidproteins)upto11-fold.DNA-protein
binding studies showed that this eﬀect was mediated via a
steroid hormone response unit in the NCCR region of the
BKV genome.
Onestudyhasinvestigatedtheinvitroeﬀectsofimmuno-
suppressive medications on BKV-speciﬁc T cell responses
[58]. Egli et al. [58] exposed peripheral blood mononuclear
cells (PBMCs) from nonimmunosuppressed BK seropos-
itive healthy volunteers to increasing concentrations of
tacrolimus, cyclosporine, MPA, and sirolimus. PBMCs were
then stimulated with BKV large T-antigen, and T-cell
responses were measured via an interferon gamma- (IFN-
γ-) linked ELISPOT assay. Both tacrolimus and cyclosporine
were shown to cause dose-dependent inhibition of IFN-γ
expression. Speciﬁcally, tacrolimus concentrations >6ng/mL
wereshown tocause>50%inhibitionofBKV-speciﬁcTcells,
while concentrations of <3ng/mL led to <30% inhibition.
Inhibition by cyclosporine was >50% at concentrations of
1920ng/mL and <30% at concentrations of <960ng/mL.
In contrast, addition of clinically relevant concentrations of
MPA (up to 8/mL) and sirolimus (up to 64ng/mL) had no
eﬀect on BKV-speciﬁc T cell IFN-γ production.
Of note, addition of increasing concentrations of sirol-
imus during T-cell expansion led to reductions in total cell
count, consistent with the well-established anti-proliferative
eﬀect of this drug. This suggests that while sirolimus had no
eﬀect on T-cell activation, it was able to inhibit BKV-speciﬁc
T-cell expansion.
The above in vitro data suggest that cyclosporine, MPA,
and sirolimus may be protective against BK replication,
as compared to tacrolimus and corticosteroids. However,
whether the postulated antiviral eﬀects of these agents are
suﬃcienttooutweightheirimmunosuppressivepropertiesin
vivocannot be elucidated from these studies.
2.2. Clinical Studies
2.2.1. Calcineurin Inhibitors, Antimetabolites, and Risk of
BKV Replication. BKVAN was essentially an unknown entity
in the era of cyclosporine-based immunosuppression, with
increasing identiﬁcation of BKVAN coinciding with inclu-
sionoftacrolimusandMPAinimmunosuppressiveregimens
[6]. This has led to the suggestion that these agents may
be speciﬁcally responsible. In support of this, multiple
retrospective and observational studies have demonstrated
substantial increases in the risk of BKV replication in the
context of tacrolimus and MPA use [14, 59, 60]. Table 2
details these studies. Of importance, however, in the ﬁrst
four of the studies tabulated [14, 20, 59, 60], conversion
to tacrolimus occurred in response to episodes of rejection.
This makes it likely that the development of BKVAN was
preceded by overall intensiﬁcation of immunosuppression.
Additionally, it is possible that the renal injury arising from
rejection episodes may have had a predisposing eﬀect [61].
In the subsequent three studies tabulated [35, 61, 62], no
information was provided as to why recipients were admin-
istered a particular calcineurin inhibitor or antimetabolite
over the other. Given the general belief that tacrolimus and
MPA have increased immunosuppressive potency compared
to cyclosporine and azathioprine, use of these drugs may
have been reserved for patients at higher immunological risk
and were possibly dosed to achieve higher levels of immuno-
suppression. Consequently, the potential for indication bias
limits any conclusions that may be drawn regarding drug-
speciﬁc eﬀects on BKV replication.
Of note, while BKVAN was not observed in previous
decades in those receiving cyclosporine-based immunosup-
pression, a more recent study of 321 KTxRs treated with
cyclosporine, azathioprine, and prednisolone showed an
incidence of BKVAN of 9.3% [63]. Given that no details
regarding inductiontherapyorpreviousepisodesofrejection
were provided, it is diﬃcult to evaluate in this study the
inﬂuence of overall immunosuppressive burden on BKV
replication. However, it does illustrate that BKVAN cannot
be solely attributed to either tacrolimus or mycophenolate-
based immunosuppression.
A number of studies have attempted to examine the
relationship between BKV replication and immunosuppres-
sive burden, as quantiﬁed by tacrolimus trough levels and
MMF and prednisolone drug doses [20, 62, 64–67]( s e e
Table 3). In three of these studies [64–66], an association was
observed between higher tacrolimus trough concentrations
and BKV replication. One of these studies [64]r e p o r t e d
that MMF and prednisolone doses were similar between
groups, while another described an association between
prednisolone but not MMF dose and BKVAN [65]. In
contrast,three studieshaveshown noinﬂuenceoftacrolimus
trough concentrations on BK replication [20, 62, 67]. Two
reported no association between BKV and MMF dose [20,
67], while one reported no association between BKV and
prednisolone dose [20].
Overall,thesedataperhaps suggestmore prominentroles
for tacrolimus and possibly prednisolone as predisposing
agents for BK replication, compared to MPA. Indeed, the
authors of the second study tabulated concluded that reduc-
ing tacrolimus and prednisolone doses while maintaining
MMF might be the most appropriateapproach for treatment
of BKVAN [68]. However, while it is generally accepted that
tacrolimus trough concentrations are a reasonable surrogate
measure of drug exposure [69], both MPA and prednisolone
are drugs with high between-subject pharmacokinetic vari-
ability leading to poor relationships between drug doses
and plasma concentrations [70–72]. Similar doses of these
drugs in those with and without BK replication cannot
be equated with similar drug exposure. As a result, it is
impossible to establish from these studies the individual
contribution of MPA and prednisolone on BKV replication
or to establish whether variable MPA and prednisolone
exposure between groups may have confounded the data
pertaining to tacrolimus concentrations.
An open-label, prospective, single-centre randomized
controlled trial (RCT) of 200 de novo adult KTxRs provides
the best evidence to date regarding the impact of the
individual calcineurin inhibitors and antimetabolites on BK
replication [73]. This study randomly assigned recipients
to tacrolimus or cyclosporine, administered in combination
with azathioprine and tapering doses of prednisolone. MMF4 Journal of Transplantation
Table 2: Clinical studies examining the inﬂuence of the calcineurin inhibitors and antimetabolites on risk of BKV replication.
Study
number
Number of
participants Study design
Primary maintenance
immunosuppressive
therapy∗
Manifestation
of BKV Results Reference
1 161 KTxRs Retrospective 73% CyA, MMF, pred;
27% Tac, MMF, pred 8w i t hB K V A N 7 of 8 recipients with BKVAN
receiving Tac, MMF, and pred [59]
2 70 KTxRs Retrospective 100% CyA, MMF, pred 5 with BKVAN BKVAN followed switch from CyA
to Tac in all 5 cases [14]
3 483 KTxRs Retrospective Not speciﬁed
100 with
viruria; 5 with
BKVAN
BKVAN followed switch from CyA
to Tac in all 5 cases [60]
4 1276 renal
biopsies Retrospective
45% CyA and pred;
11% Tac and pred;
30% CyA, MMF, and
pred;
8% Tac, MMF, and pred;
5% CyA and Aza;
3% CyA, SLM, and pred
7w i t hB K V A N
4 of 7 recipients with BKVAN were
receiving Tac, MMF, and pred; use
of this combination associated with
an 8-fold higher incidence and
13-fold higher risk of BKVAN
(multivariate odds ratio of 12.7
(95% CI 2.1–7.8))#
[20]
5 880 KTxRs Retrospective
75% CyA, 16% Tac, 7%
SLM;
64% Aza, 34% MMF;
“Almost all” pred
129 with
viruria; 39 with
BKVAN
Both Tac and MMF independently
associated with increased risk of
high-titre viruria (hazard ratios of
4.9 (95% CI 3.1–7.3) and 4.6 (95%
CI 3.1–6.7) for the 2 drugs, resp.),
and for BKVAN (hazard ratios of
3.3 (95% CI 1.5–7.6) and 3.5
(95%CI 1.6–7.5), for the 2 drugs,
resp.).
[61]
63 2 K T x R s Prospective
observational
59% CyA, MMF,
pred-based;
41% Tac, MMF, pred
20 with
viruria∧;2 3
with viraemia
Higher rate and risk of viremia with
Tac as compared to CyA (77%
versus 33%, P = .03; relative risk for
viraemia with tacrolimus use 2.3
(95% CI 1.1–4.9))
[62]
7 48,292
KTxRs Retrospective
20% CyA, 76% Tac, 4%
no CNI;
1% Aza, 82% MMF, 17%
no antimetabolite
1474 treated for
BKV replication
Lower adjusted hazard ratio for
treatment of BKV replication with
CyA-based as compared to
Tac-based immunosuppression
(0.53 (95% CI 0.45, 0.63);
P<. 0001); trend towards reduced
risk with Aza compared to MMF
(0.42 (95% CI 0.17, 1.01);
P = .0517).
[35]
∗Refers to initial maintenance regimen employed at timeof transplantation; not necessarilythe regimen employed at time of diagnosis with BKV replication.
#For the analysis relating to the inﬂuence of immunosuppression on BKVAN, the KTxRs with BKVAN were compared to a control group (n = 42; matched
for transplant date and baseline immunosuppression)rather than to study cohort as a whole.
∧Includes recipients in whom viruria and viraemia were simultaneouslydetected.
Aza: azathioprine; BKV: BK virus; BKVAN: BKV-associated nephropathy; CyA: cyclosporine; KTxRs: kidney transplant recipients; MMF: mycophenolate
mofetil; pred: prednisolone; SLM: sirolimus; Tac: tacrolimus.
(1g twice daily) was substituted for azathioprine in those
considered to be at high immunological risk or with a
history of gout (49% in the tacrolimus group and 35% in
the cyclosporine group). No diﬀerence was observed in the
incidence of viruria in recipients assigned to cyclosporine
compared to tacrolimus (36% versus 31%; P = .61) or
in recipients who received azathioprine compared to MMF
(33%versus38%;P = .52).Similarly,therewasnodiﬀerence
in viraemia with tacrolimus compared to cyclosporine (12%
versus11%;P = 1.0)orwith azathioprine versusMMF(13%
versus 9%; P = .46). While viruria was highest with the
combination of tacrolimus and MMF (46%) and lowest with
cyclosporine and MMF (13%) (P = .005), viraemia tended
to be highest with cyclosporine and azathioprine (15%)
and lowest with cyclosporine and MMF (4%) (P = .27).
These data fail to demonstrate a single role of any particular
CNI or antimetabolite in promoting BKV replication. The
ﬁndingofthehighestincidenceofBKviruriawithtacrolimus
and MMF does suggest that this combination may be the
most permissive for BKV replication. However, it should be
noted that cyclosporine lowers MPA concentrations while
tacrolimusdoesnot [70], raising thepossibility ofconfound-
ing due to higher MPA exposure in the tacrolimus arm of
the trial (MPA concentrations not measured). Further, thoseJournal of Transplantation 5
Table 3: Clinical studies examining the relationship between BKV replication and drug exposure.
Study
number
Number of
participants Study design Immunosuppression
exposure measures
Manifestationof
BKV Results Reference
1 38 pancreas
Tx recipients Retrospective Tac C0 concentrations,
MMF, and pred dose 4 with viruria
Tac C0 higher in those with viruria
at 1, 3 and 12 months post-tx (22 ±
3.1 versus 16 ± 0.9ng/mL, P = .03;
26 ± 4.8 versus 14 ± 1.0ng/mL,
P = .0005; 19 ± 0.6 versus 12 ±
0.7ng/mL P = .0008); no inﬂuence
of MMF or pred dose
[65]
2
33 KTxRs
with BKVAN,
66 matched
controls
Retrospective Tac C0 concentrations,
MMF, and pred dose 33 with BKVAN
Higher Tac C0 and prednisolone
dose associated with increased risk
of BKVAN (OR 1.3. 95% CI
1.02–1.7; P = .03; and OR 1.22,
95% CI 1.04–1.4; P = .02, resp.); no
inﬂuence of MMF dose
[66]
3 575 KTxRs Retrospective Tac C0 concentrations 32 with BKVAN
Higher Tac C0 associated with
higher incidence of BKVAN (10.5%
versus 2.5%, P<. 09001)
[64]
4
7K T x R sw i t h
BKVAN, 42
matched
controls#
Retrospective Tac C0 concentrations,
MMF, and pred dose 7w i t hB K V A N No inﬂuence of Tac C0, MMF, or
pred dose on BKVAN [20]
53 2 K T x R s Prospective
observational
CyA and Tac C0
concentrations
20 with viruria∗;
23 with viraemia
No inﬂuence of CyA or Tac C0 on
viruria, viraemia or BKVAN [62]
6 120 KTxRs Prospective
observational
Tac C0 concentrations,
tac, and pred dose 37 with viruria No inﬂuence of Tac C0 or tac or
pred dose on viruria [67],
∗Includes recipients in whom viruria and viraemia were simultaneouslydetected.
#Matched for transplant date and baseline immunosuppression.
BKV: BKvirus; BKVAN: BKV associatednephropathy; CI: conﬁdence interval; CyA:cyclosporine;KTxRs: kidneytransplantrecipients;MMF: mycophenolate
mofetil; OR: odds ratio; pred: prednisolone; Tac: tacrolimus.
with both transient and sustained viruria were included in
this analysis. Given that transient viruria can be observed
in a variety of individuals including healthy donors and
nonkidney solid organ transplant recipients, this data may
be misleading with regard to the inﬂuence of immuno-
suppression on clinically signiﬁcant BKV replication. The
relative eﬀects of cyclosporine versus tacrolimus on BKVAN
are currently being assessed as a secondary end-point of
theDIRECT(DiabetesIncidenceafterRenaltransplantation:
NEoral C-2 monitoring versus Tacrolimus) trial, a random-
ized, six-month, open label, international multicentre trial
in which 682 patients who received kidney transplants were
treated with either cyclosporine microemulsion formulation
or tacrolimus to prevent organ rejection [74].
2.2.2. Steroids and Risk of BKV Replication. Use of pulse
steroids as treatment for acute rejection has been indepen-
dently associated with BKV replication and BKVAN [21].
However, as discussed above, it is diﬃcult to diﬀerentiate
whether BKVAN following rejection results from augmented
immunosuppressionorfromadrug-speciﬁceﬀect.Therehas
been only limited study of the role of maintenance steroid
therapy in promoting BKV replication. In a nonrandomized
prospectivestudyof120KTxRsofwhom71weremaintained
onsteroidsand49weretreatedwithearlysteroidwithdrawal,
Dadhania et al. [67] identiﬁed steroid maintenance therapy
as an independent risk factor for BKV replication (odds
ratio 8.3 (95% CI 2.1, 32.7); P = .003)). A retrospective
single-centre study of 213 kidney and 14 pancreas-kidney
transplant recipients found a lower incidence of BKVAN
in those that had steroids ceased early or withdrawn, as
compared to those that continued on steroids (0% versus
3.5%; P<. 05) [75]. A US OPTN database review of
48,292 KTxRs [35] reported that the risk of treatment
for BKV replication was increased in those discharged on
maintenance steroids versus those that were not (adjusted
hazards ratio 1.16 (95% CI 1.02, 1.31); P = .0237)). None
of these studies reported on whether immunological risk
statusand immunosuppressiontarget levelsdiﬀeredbetween
groups. However, the study of Dadhania et al. [67]u s e d
multivariable logistic regression analysis to account for the
eﬀects of antihuman thymocyte globulin (ATG) induction,
tacrolimus trough levels, tacrolimus and MMF dose and
acute rejection, while the database review [35]ﬁ t t e daC o x
proportional hazards model to account for a very large
number of possible confounding variables.
2.2.3. Calcineurin Inhibitor-Free, Mammalian Target of
Rapamycin (mTOR-) Based Regimens and Risk of BKV
Replication. BKVAN has been uncommonly observed in
patients receiving calcineurin inhibitor-free or mTOR-based
regimens. A small case series reported the development6 Journal of Transplantation
of BKVAN in 3 KTxRs maintained on sirolimus, pred-
nisolone, and MMF [76]. None had been previously exposed
to calcineurin inhibitors or experienced prior rejection.
Two had received interleukin-2 antagonist induction ther-
apy, while one had received thymoglobulin. A retrospec-
tive study reported nine cases of BKVAN in 344 kid-
ney and 34 pancreas-kidney transplant recipients treated
with sirolimus-based immunosuppression (cyclosporine-
sirolimus in 6 recipients, tacrolimus-sirolimus in 1 recipient,
MMF-sirolimus in 1 recipient, and cyclosporine-MMF-
sirolimusin1recipient)[77].Eightofnine patientshadbeen
previously exposed to ATG, while 3 had experienced acute
rejection. In the US OPTN database review [35], 5380 of
48,292 KTxRs were discharged on mTOR-based immuno-
suppression, of whom 83 (1.74%) received treatment for
BKVAN within 2 years of transplant. Multivariable analysis
showed a reduction in risk of treatment for BKV replication
with use ofan mTORat discharge, ascompared to no mTOR
use (adjusted hazards ratio 0.69 (95% CI 0.54, 0.89); P =
.0048)).
2.2.4.LymphocyteDepleting TherapyandRiskofBKVReplica-
tion. T h em a j o r i tyo fs t u d i e sh a v es h o w na ni n c r e a s ei nB K V
replication following use of lymphocyte depleting agents for
induction or treatment of rejection. This is not surprising
given the immunosuppressive potency of these agents. In
a study of 120 KTxRs, multivariable analysis showed an
independent inﬂuence of ATG induction on risk of BKV
replication (odds ratio 5.83 (95% CI 1.60, 21.35); P = .008)
[67]. Similarly, in the retrospective study of 344 kidney
and 34 pancreas-kidney transplant recipients mentioned
above [77], multivariable analysis correlated exposure to
ATGforeitherinductionorrejectiontreatment withahigher
incidence of BKVAN (3.53% versus 1.44%; P = .048). In
a retrospective analysis of renal biopsy and urine cytology
samples from 880 KTxRs, use of ATG for induction exerted
an independent risk for developing both high level viruria
and BKVAN [61]. In a prospective study of 78 KTxRs, those
with viraemia were more likely to have received antirejection
treatment with ATG than those without evidence of BKV
replication (60% versus 20%; P = .008) [21]. Interestingly,
in the US OPTN database review [35], induction therapy
with thymoglobulin was associated with an increased risk
of treatment for BKV (adjusted hazards ratio 1.42 (95% CI
1.24, 1.63); P<. 0001), but induction therapy with ATG had
no independent eﬀect (adjusted hazards ratio 01.19 (95% CI
0.73, 1.95); P = .4792).
3.ImmunosuppressionReductionas
a TreatmentStrategyforBKV Replication
To date, there are no antiviral drugs available with spe-
ciﬁc activity against BKV [37]. While various therapies
have been tried, including cidofovir [78, 79], intravenous
immunoglobulin [80], and leﬂunomide [81], success has
been variable and none have been appropriately studied in
a randomized controlled clinical trial [37]. Consequently,
reduction of immunosuppression remains the mainstay
of treatment, despite the increased risk of immunological
allograft damage associated with this approach. Multiple
strategiesarecurrentlyutilised,includingreducingorceasing
antimetabolite therapy, lowering calcineurin inhibitor target
concentrations, switching from tacrolimus to cyclosporine,
and conversion from calcineurin inhibitor to sirolimus [13,
82]. However, as outlined in a recent systematic review [83],
published reports on these protocols have yielded mixed
results, and no randomized controlled trials have compared
one strategy with another.
Of note, in more recent times, many centers have insti-
tutedroutinescreeningofurineorbloodforBKVDNA.Such
programs have reported signiﬁcant improvements in graft
outcomes, possibly due to early detection of viral presence
and reduction of immunosuppression prior to the onset of
graft damage [17, 21, 84, 85].
4.Conclusions
Immunosuppression is clearly a major risk factor for BKV.
This is evidencedby theincrease in viral replicationobserved
in immunosuppressed populations and the decrease in viral
replication that follows immunosuppression reduction. To
date, however, there is no conclusive evidence that any one
drug has speciﬁc inﬂuence over another in regard to the
development of posttransplant BKV infection.
Cyclosporine, mycophenolate, and sirolimus have all
been shown to possess antiviral activity against BKV in
vitro. Alternatively, in vitro data suggest that tacrolimus
has no inhibitory potential, while corticosteroids may in
fact enhance BKV replication. However, whether these
characteristics are suﬃcient to counteract or exacerbate the
immunosuppressive properties of these drugs in vivo has not
been conﬁrmed in clinical trials.
In KTxRs, BKV infection has been observed under
all combinations of immunosuppression. This illustrates
that no one drug is either necessary or suﬃcient. While
multiple studies have associated tacrolimus and MMF use
with increased risk, the majority of these were retrospective
or observational in nature and confounded by variable
and uncontrolled use of additional immunosuppression.
Only one RCT has addressed this issue. This showed no
independent inﬂuence of either tacrolimus or cyclosporine,
nor any independent eﬀect of either azathioprine or MMF.
However, again, results were likely cofounded by variable
immunosuppressive cotherapy exposure in the two arms of
this trial. A small number of studies have shown lower inci-
dence of BKV replication under steroid minimisation, CNI-
free, or mTOR-based regimens. However, given that such
protocols are often reserved for lower immunological risk
patients requiring lower total doses of immunosuppression,
little can be interpreted from this data.
There is general consensus that reduction of immuno-
suppression is appropriate for management of signiﬁcant
BKV replication. Further, it appears that early detection and
intervention are important in preventing irreversible graft
damage. However, there has been limited comparison of the
various approaches, with the result that there is no good
evidence to support one strategy over another.Journal of Transplantation 7
For the future, prospective trials speciﬁcally designed
to address the impact of the various immunosuppressive
agents on risk of BKV replication are required. To prevent
confounding of results due to variable cotherapy exposure,
it is vital that these studies incorporate proper immunosup-
pression exposure measures (e.g., MPA drug concentration
measurements). Additionally, assays are becoming available
that allow direct assessment of immune cell function [86].
Incorporation of these measures could prove invaluable
in distinguishing postulated antiviral eﬀects of the various
drugs from the inﬂuence of drug-induced immunosuppres-
sion.
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